Clinical Trials

Endocrine

Hyperinsulinism, Insulinoma, Congenital Hyperinsulinism

NCT01468532 2021-03-25

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 1/2 Completed

18 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT01270321 2021-02-17

Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer

42 enrolled 11 charts

Head & Neck

Thyroid Neoplasms

NCT01385956 2020-09-28

SOM 230 and Gemcitabine in Advanced Pancreatic Cancer

20 enrolled

Phase 4 Active not recruiting

Adenocarcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT02775227 2020-08-24

HYPAR

126 enrolled

Pancreatic Fistula, Pancreatic Neoplasms

NCT01469572 2018-10-18

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

EndocrineGastrointestinalNET

13 enrolled

Liver Neoplasms, Neuroendocrine Tumors

NCT02021942 2018-02-05

Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size

16 enrolled 11 charts

Thoracic

Primary Inoperable Thymoma

NCT02780882 2018-01-26

SOM230 Ectopic ACTH-producing Tumors

ACTH Syndrome, Ectopic

NCT01372618 2017-12-27

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor

Phase 1/2 Terminated

9 enrolled 3 charts

Breast

Carcinoma, Intraductal, Noninfiltrating

NCT00929669 2017-11-28

LAR

Phase 2 Terminated

2 enrolled 3 charts

Endocrine

Pituitary Neoplasms

NCT01252251 2017-08-01

RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

14 enrolled 12 charts

Dermatologic

Uveal Melanoma

NCT01639352 2017-07-12

Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma

20 enrolled 12 charts

Carcinoma, Hepatocellular

NCT01356862 2017-01-25

SOM 230

91 enrolled

Breast

Breast Neoplasms

NCT01372644 2016-12-05

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial

15 enrolled

Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT01617733 2016-11-02

Pasireotide Therapy in Patients With Nelson's Syndrome

Phase 2 Terminated

8 enrolled

Nelson Syndrome

NCT00804336 2016-10-19

Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors

22 enrolled

EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT01620138 2016-08-22

Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas

Phase 2/3 Completed

21 enrolled 4 charts

Prolactinoma

NCT01625520 2016-04-25

SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer

19 enrolled

Carcinoma, Medullary

NCT01488487 2016-04-07

Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

24 enrolled 17 charts

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01329289 2016-02-12

SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

Plasma cell

Multiple Myeloma

NCT00994110 2016-02-01

Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess

Phase 3 Completed

439 enrolled 7 charts

Pancreatic Neoplasms

NCT00813592 2014-06-11

Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma

Phase 2 Terminated

2 enrolled 6 charts

CNS

Meningioma, Neoplasms

NCT01234974 2013-01-10

IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus